Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: Immunoregulatory aspects and role of donor T and ASGM1-positive cells

Transplantation

Volumn 70, Issue 2, 2000, Pages 348-353

  Sefrioui, H ^a   Billiau, A D ^a   Waer, M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOREGULATION; LEUKOCYTE TRANSFUSION; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034721042     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200007270-00020     Document Type: Article

References (39)

1. Bortin M, Horowitz M, Rimm M. Progress report from the International Bone Marrow Transplant Regstry. Bone Marrow Transplant 1992; 10: 113.
2. Weiden Pl, Strob R, Tsoi M, Graham TC, Lerner KG, Thomas D. Infusion of donor lymphocytes into stable canine radiation chimeras: implication for mechanisms of transplantation tolerance. J Immunol 1976; 116: 1212.
3. Johson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host-disease. Bone Marrow Transplant 1993; 11: 329.
4. Porter DL, Roth MS, Mcgarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic leukemia. N Engl J Med 1994; 330: 100.
5. Drobuski WR, Hessner MJ, Klein JP, et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusion as a strategy to treat chronic phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 1999; 94 (2): 434.
6. Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Ann Rev Med 1999; 50: 369.
7. Buzyn-Veil A, Belanger C, Audat F, et al. Sustained complete cytologic and molecular remission induced by donor leucocyte infusions alone in an acute myeloblastic leukaemia in relapse after bone marrow transplantation. Br J Haematol 1996; 92: 423.
8. Sakai R, Maruta A, Yanoma S, et al. Effect of sublethal total body irradiation on acute graft-versus-host disease and graft-versus-leukemia effect in SCID mice. Bone Marrow Transplant 1997; 20: 183.
9. Zeis M, Uharek B, Glass J, et al. Allogeneic MHC-mismatched activated natural killer cells administrated after bone marrow provide a strong graft-versus-leukemia effect in mice. Br J Haematol 1997; 96: 757.
10. O'Kunewik JP, Kociba DL, Machen LL, Buffo MJ. Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of murine type-C retroviral leukemia. Bone Marrow Transplant 1995; 16: 451.
11. Glass B, Uharek L, Gassmann W, Focks B, Bolouri H, Loffler H. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host-disease. Ann Haematol 1992; 64: 255.
12. Glass B, Uharek L, Zeis M, Loffler H, Muller W, Gassmann W. Graft-versus-leukemia activity can be predicted by natural cytotoxicity against leukemia cells. Br J Hematol 1996; 93: 412.
13. Jiang Y, Cullis J, Kanfer E, et al. T cell and NK cell mediated graft-versus-leukemia reactivity following donor buffy coat marrow transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1993; 11: 133.
14. Sefrioui H, Billiau AD, Overbergh L, Rutgeerts O, Waer M. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen mismatched bone marrow chimeras. Transplantation 1999; 68: 1560.
15. Salam A, Waer M. Graft-versus-host reactivity and graft-versus leukemia effect in murine allogeneic bone marrow chimeras conditioned with TBI or TLI. Transplantation 1996; 61: 826.
16. Sefrioui H, Moodley J, Rutgeerts O, Waer M. Stable mixed chimerism induced by total lymphoid irradation or by total body irradiation is maintained by different mechanisms and leads to different graft-versus-leukemia or graft rejection reactions. Transplant Proc 1997; 29: 2352.
17. Sefrioui H, Billiau AD, Overbergh L, Rutgeerts O, Waer M. Tolerance in Mlsa mismatched chimeras prepared with allogeneic bone marrow alone or in combination with syngeneic bone marrow. Transplant Proc 1998; 31: 702.
18. Bortin MM, Rimm AA. Increasing utilization of bone marrow transplantation: II results of 1985-1987 survey. Transplantation 1989; 48: 453.
19. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukemia. Lancet 1987; 2: 175.
20. Vallera DA, Soderling CC, Carlson GJ, and Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice. II: T cell requirements for engraftment in total lymphoid irradiation-conditioned recipients. Transplantation 1982; 33: 243.
21. Weiden PL, Horowitz MM. Graft-versus-leukemia effect in clinical bone marrow transplantation. In: Graft-versus-host-disease. New York: Marcel Decker, 1990; 691.
22. Johnson BD, Becker EE, Truitt RL. Graft-versus-host and graft-versus-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 1999; 5 (3): 123.
23. Grigg A, Szer J Successful donor leucocyte infusion for chronic myeloid leukemia relapsing in accelerated phase after T cell-replete unrelated marrow transplantation. Bone Marrow Transplant 1996; 18: 647.
24. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 1995; 86: 2041.
25. Van Rhee F, Lin F, Cullis JO, et al. relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: the case for giving donor leucocyte transfusions before the onset of heamatologic relapse. Blood 1994; 83: 3377.
26. Bennett S, Carbone F, Toy T, Miller J, Heath W. B cells directly tolerize CD8+ cells. J Exp. Med 1998; 188: 1977.
27. Weiss L, Slavin S. Prevention and treatment of graft-versus-host disease by down regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant 1999; 23 (11): 1139.
28. Johnson BD, Hanke C, Truitt R. The graft versus leukemia effect of post-transpant donor leukocytes infusion. Leuk Lymphoma 1996; 23: 1.
29. Johnson BD, Truitt R. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-versus-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995; 85: 3302.
30. Palathumpat V, Dejbakhsh J, Strober S. The role of CDS positive T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 1995; 60: 355.
31. Sykes M, Abraham K, Pearson DA. IL-2 reduces graft-versus-host-disease and preserve graft-versus-leukemia effect by selectively inhibiting CD4 positive T cells activity. J Immunol 1993; 150: 197.
32. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 1997; 157: 167.
33. Zeis M, Uharek L, Glass B, et al. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995; 59: 1734.
34. Hercend T, Takvorian T, Nowill A, et al. Characterisation of natural killer cells with anti-leukemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722.
35. Uharek L, Glass B, Gasta T, et al. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model. Bone Marrow Transplant 1993; 12: S57.
36. Vourka-Karussis U, Ackerstein A, Pugatsh T, Slavin S. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models. Exp Hematol 1999; 27 (3): 461.
37. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest 1992; 10: 19.
38. Shiloni E, Lafreniere J, Mule J, Schwarz L, Rosenberg S. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukine-2 on established pulmonary and hepatic metastases in mice. Cancer Res 1986; 45: 5633.
39. Younes E, Haas G, Dezso B, et al. Local tumor irradiation augments the response to IL-2 therapy in murine renal adenocarcinoma. Cell Immunol 1995; 165: 251.